Lethal Transaldolase Deficiency Mimicking Gestational Alloimmune Liver Disease: Prenatal Sonography and Identification of a Novel TALDO1 Variant
American Journal of Perinatology Reports · 01.07.2026 · 16 (03) · e195-e199
DOI: 10.1055/a-2946-5351 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Perinatology Reports, erschienen am 01.07.2026. Verfasst von Tiara M Adeniji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science StudiesRobbins College of Health and Human Sciences, Baylor UniversityWacoTexasUnited States. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The objective of this study is to describe the prenatal sonographic and neonatal features of two siblings with lethal transaldolase deficiency and highlight its phenotypic overlap with gestational alloimmune liver disease (GALD). Study Design This is a retrospective review of consecutive pregnancies in a single family, analyzing sequential prenatal ultrasound surveillance, maternal therapeutic interventions, neonatal clinical course, and postmortem trio exome sequencing.
Results
Both siblings exhibited severe early-onset fetal growth restriction, echogenic bowel, neonatal hemochromatosis, and hypertrophic cardiomyopathy. Because the clinical presentation during the first pregnancy closely mimicked GALD, the second pregnancy was treated empirically with intravenous immunoglobulin (IVIG), which proved entirely ineffective. Subsequent exome sequencing revealed compound heterozygous variants in the TALDO1 gene, including a novel pathogenic variant (p.Arg239Cys). These findings demonstrate that the hepatic pathology in transaldolase deficiency is a primary metabolic process rather than an antibody-mediated alloimmune process.
Conclusion
Transaldolase deficiency should be considered in the differential diagnosis for fetuses presenting with unexplained severe growth restriction accompanied by echogenic bowel or hepatic echogenicities or in neonates with fulminant liver failure, particularly when associated with cardiomyopathy. This case highlights the value of performing prenatal exome sequencing prior to initiating targeted therapies like IVIG. Establishing a definitive genetic diagnosis prevents the utilization of futile, resource-intensive treatments, optimizing patient care and prognostic counseling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Science StudiesRobbins College of Health and Human Sciences, Baylor UniversityWacoTexasUnited States.
- Maternal Fetal Center, Valley Children's HealthcareMaderaCaliforniaUnited States.
- Department of GeneticsKaiser Permanente Health CareOaklandCaliforniaUnited States.
ORCID-Profile: Sanmaan Basraon
Zitieren
APA
Adeniji, T. M., Carmichael, J., Basraon, S., Hole, J., Mendelsohn, B. A., & Adeniji, B. A. (2026). Lethal Transaldolase Deficiency Mimicking Gestational Alloimmune Liver Disease: Prenatal Sonography and Identification of a Novel TALDO1 Variant. American Journal of Perinatology Reports, 16(03), e195-e199. https://doi.org/10.1055/a-2946-5351
Vancouver
Adeniji TM, Carmichael J, Basraon S, Hole J, Mendelsohn BA, Adeniji BA. Lethal Transaldolase Deficiency Mimicking Gestational Alloimmune Liver Disease: Prenatal Sonography and Identification of a Novel TALDO1 Variant. American Journal of Perinatology Reports. 2026;16(03):e195-e199. doi:10.1055/a-2946-5351
BibTeX
@article{Adeniji2026,
author = {Adeniji, Tiara M and Carmichael, Jason and Basraon, Sanmaan and Hole, James and Mendelsohn, Bryce A and Adeniji, Beni A},
title = {Lethal Transaldolase Deficiency Mimicking Gestational Alloimmune Liver Disease: Prenatal Sonography and Identification of a Novel TALDO1 Variant},
journal = {American Journal of Perinatology Reports},
year = {2026},
volume = {16},
number = {03},
pages = {e195--e199},
doi = {10.1055/a-2946-5351}
}
EUVIMED